Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sirolimus in Prevention of aGVHD in Maternally Engrafted (TME) Severe Combined Immunodeficiency (SCID) Infants Receiving Unconditioned Hematopoietic Stem Cell Transplant (HSCT)

NCT02177760 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT02177760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02177760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sirolimus in Prevention of aGVHD in Maternally Engrafted (TME) Severe Combined Immunodeficiency (SCID) Infants Receiving Unconditioned Hematopoietic Stem Cell Transplant (HSCT)
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Withdrawn
Start date
July 31, 2014
Completion date
November 30, 2015
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe combined immunodeficiency, stem cell transplant, transplacental maternal engraftment